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1INTRODUCTION
Discovery of CART
Cocaine-induced molecular alterations are believed to be responsible for many of 
the drug's behavioral consequences. Attention has therefore been focused on determining the 
changes in gene expression after cocaine treatment. Changes in expression of a number of 
genes have been observed in response to acute and chronic cocaine administration. CART 
(i.e., Cocaine- and Amphetamine-Regulated Transcript) gene which was discovered in 1995 
by Douglass et al. as an mRNA transcript by differential display method is included in this 
gene group. CART mRNA was increased in rat striatum and nucleus accumbens after acute 
cocaine and amphetamine treatment. The profile of CART mRNA within the cerebellum, 
striatum and hippocampus was determined by Northern blot analysis and surprisingly showed 
transcriptionally silent brain regions in the hippocampus after acute cocaine and amphetamine 
treatment. Douglass et al. (1995) already pointed out that CART was a new, previously 
uncharacterized rat mRNA that was not significantly related to any known mRNA.
Characteristic features of CART DNA and mRNA
CART mRNA expression patterns in the human brain were qualitatively similar to 
the rat brain CART mRNA distribution indicating that the protein product of the CART 
mRNA plays a functional role or roles across the mammalian species. Since, CART mRNA 
has been described in many vertebrate species including rodents (mouse, rat), goldfish and 
human. Comparing human CART cDNA to rat CART cDNA, the human CART cDNA 
sequence was about 80 % identical to the rat cDNA with about 92 % homology in the protein 
- coding region. Subsequently, the CART mouse gene was mapped to chromosome 13 
encoding a 2.5 kb segment, and the human gene was mapped to chromosome 5 containing 
approximately 2 kb segment, while the rat CART gene has not been identified yet. The 
chromosomal mapping made possible to analyze the genetic variations of CART gene. 
Several polymorphisms have been described in the 3' UTR region and 5’ flanking region. To 
confirm this association between the CART 5' flanking region polymorphic site and the 
inherited obesity, farther investigations are necessary. Additional rat CART cDNA sequence 
analysis characterized the rat CART mRNA in helping to understand the appearance of an 
RNA doublet following Northern blot analysis. TTie characterization revealed that in the 
termination of synthesis of CART mRNA, alternate poly A site utilization plays a role in the 
3* non-coding region which resulted in the appearance of an RNA doublet, either 
approximately 700 or 900 bases in length. Moreover, alternative splicing produced further 
diversity within the coding region of the transcripts in the rat, and resulted in two mRNA 
species, one with the absence of an in frame 39 base insert within the protein coding region, 
called short form of CART mRNA apart from the 700 or 900 bases in length. In all 
probability, the observed CART mRNA doublet following Northern blot analysis corresponds 
to four mRNAs instead of two mRNAs. The shorter species was about twice as abundant as 
the longer one in rat. Interestingly, in human, the short form was the only one found.
Characteristic features of CART peptides
Rat CART cDNA sequence analysis also helped to predict the translation product 
of CART gene. The synthesized protein: either 129 or 116 amino acids in length depending
2on the alternative splicing of 39 bases in the coding region. Examination of the deduced 
amino acid sequence suggested that the CART product would be a neuropeptide that was 
secreted and processed. This suggestion was based on the identification of a common 
hydrophobic leader sequence and the amino terminus indicating involvement in a secretion 
pathway, and several pairs of basic amino acids, which are commonly found in propeptides 
that are processed before subsequent utilization.
Thim et al. (1999) proved this hypothesis by purifying CART peptides from 
adrenal gland, hypothalamus, nucleus accumbens and pituitary gland of die rat and 
determined the peptide structures by using microsequencing and mass spectrometry. It 
demonstrated a tissue-specific processing of CART that may point to different biological 
functions of CART peptides in the peripheral and central nervous system. From the adrenal 
gland, the CART (1-89) and CART (10-89) peptides were isolated. In contrast, from the 
hypothalamus and nucleus accumbens, shorter form peptides CART (42-89) and CART (49- 
89) were purified. Surprisingly, the long splice variant was found in all of the tissues 
examined. Kuhar et al. (1999) confirmed this processing by Western blot analysis. In order to 
examine the processing and localization of CART putative peptides in the brain, polyclonal 
antibodies were prepared against several CART peptide fragments. Using these antibodies, 
several different fragments of the CART protein were identified in the brain.* It seemed that 
the two fragments were likely to be produced from the pre-proCART protein and presumably 
they had different processing modifications. These antibodies mentioned above were also 
used for immunohistochemical staining to determine the localization of CART peptides. The 
distribution of CART peptides corresponded to the expression pattern of CART mRNA.
It has been shown that CART peptides are neurotransmitters. Electronmicroscopic 
analysis showed that the peptides were found exclusively in large dense vesicles in neurons in 
the brain, processed to smaller peptides and released by calcium-dependent mechanisms into 
synapses. CART peptides are co-localized with numerous well-known neurotransmitters like 
GABA, galanin, MCH, oxytocin, POMC, somatostatin, as well as nitric oxide synthase.
These neuroanatomical findings suggested various possible physiological functions. CART 
peptides could play a role in the stress response, feeding behavior, immune function, 
autonomic regulation, fluid balance, metabolic processes, sexual function and endocrine 
control. The putative functions are listed in Table 1. In order to prove presumed physiological 
functions, CART peptides were made by using molecular biology. The preparation of CART 
peptides by peptide synthesis was very difficult. A yeast expression system was developed for 
the production of relatively large amounts of CART peptides including the naturally occurring 
CART (55-102) as well.
Injection of the peptides into the brain resulted in behavioral effects. Strong 
evidence implicates CART in the control of feeding behavior. As mentioned above, CART is 
highly expressed in the arcuate and paraventricular nuclei of the hypothalamus. These areas 
are known to be involved in the control of appetite. CART neurons show c-Fos- 
immunoreactivity after intravenous injections of leptin in rats. Hypothalamic CART mRNA 
levels are decreased in hypoleptinemic states, such as in the ob/ob mouse, and after prolonged 
fasting. In these conditions, CART expression is restored by leptin administration. 
Intracerebrovascular injection of recombinant CART peptide into rats and mice inhibits 
normal and starvation-induced feeding and blocks the feeding response induced by 
neuropeptide Y. Conversely, after central administration of anti-serum against CART in rats, 
feeding response was increased. These data strongly implicate CART as an endogenous 
satiety factor. However, a new finding suggests that CART peptides may stimulate feeding at 
least in the hypothalamus.The injection of multifunctional CART peptides into the VTA
3produces psychostimulant-like behavioral effects including increased locomotor activation 
and establishment of conditioned place preference. There is also evidence that the CART 
protein has neurotrophic action in vitro. The short form of CART protein, which is found in 
humans, has been shown to have neurotrophic properties in several primary-cell-culture 
neurons. These include dopaminergic, hippocampal and retinal neurons, and motoneurons. 
The effects produced include increased dopamine uptake, increased cell survival and 
increased neurite length. In a recent study, Balkan et aJ. suggested the involvement of the 
CART peptide in the stress response and its modulation by glucocorticoids. CART studies 
predict its role in development and neurotrophic activity, too.
Even with all of the information available, the CART receptor has not been found 
yet. Apart from the receptor missing, substantial evidence has been gathered that CART 
peptides are involved in psychostimulant - like effects, feeding, and stress. To understand and 
confirm the multifunctional effects of CART protein, the CART receptor needs to be 
identified. Furthermore, elucidating the detailed molecular mechanism involved in the 
regulation of CART gene may serve as a model to address the multifunctional behavior of 
CART peptides.
First, the CART was identified as an upregulated mRNA transcript after acute 
cocaine and amphetamine treatment. Secondly, the cyclic adenosine 3’, 5’-monophosphate 
(cAMP)- protein kinase A (PKA) signal tranduction pathway is known to be induced by 
cocaine administration in rat nucleus accumbens. Thirdly, it has been reported that after 
cAMP activation CART mRNA was increased in GH3 cells. Therefore, the possibility of 
PKA-mediated transcriptional regulation in the CART gene expression is more than likely.
In this study, based on the aforementioned evidence, the attention was focused on 
determining regulatory mechanisms driving the changes in the CART gene expression.
4Table l.T h e  possible physiological functions of CART peptide
Feeding behavior
Paraventricular nucleus of the hypothalamus
Arcuate nucleus
Parabrachial nucleus
Perifomical cells in the hypothalamus
Stress
Hypothalamic nuclei 
Pituitary ( anterior or posterior)
Adrenal medulla
Intermediolateral cell columns of the spinal cord
Sensory processing
Mitral and tufted cells of the olfactory bulb
Some retinal ganglion cells
Layer IV of the cerebral cortex in barrels
Thalamic relay nuclei
Nucleus of the solitary tract
Lamina 1 of the spinal cord
Afferent vagal fibres
Reward and reinforcement
Nucleus accumbens
Ventral tegmental area of the midbrain
Basolateral amygdala
Central autonomic network
Nucleus of solitary tract 
Nucleus ambigous 
Central nucleus of amygdale 
Paraventricular nucleus of hypothalamus
5OBJECTIVES OF THE RESEARCH PROJECT
1. Identifying transcription binding sites for the CART promoter region using the Trasfact 
computer program.
2. To determine whether the putative transcription binding sites on the CART promoter 
participate in the activation of CART gene expression in GH3 cells.
3. Characterizing the relevant transcription factors and their functions which can be recruited 
into the CART promoter during CART gene activation.
4. To identify transcriptional regulatory networks that can play substantial role in the 
regulation of CART mRNA expression.
EXPERIMENTAL PROCEDURES
CELL LINES 
List of cell lines used:
GH3 rat pituitary adenoma cell line
AtT20 mouse pituitary adenoma cell line 
PC12 rat phaeochromocytoma cell line
CELL CULTURE
PC12 cells were grown in Dulbecco's modified eagle medium (DMEM)> supplemented with 
5% calf serum and 10% horse serum. GH3 cells were maintained in F-12K Ham's (Kaighn's 
modification) media supplemented with 12%. horse and 2.5 % fetal bovine serum.Mouse 
AtT20 cells were grown in Dulbecco's Minimal Essential Medium supplemented with 10 % 
horse serum. AU tissue cultures were maintained in a humidified incubator at 37 °C under 5 % 
C 02.
SEQUENCING AND ANALYSIS OF THE MOUSE CART GENE PROMOTER 
REGION
A BamRl subclone, BAM5'C (approximately 9.5 kb in length), containing the entire CART 
gene was generated. The CART 5'-flanking region in BAM5'C (BglWSacl segment) was 
sequenced. All sequences were determined by cycle sequencing reactions.
The sequenced region was analyzed for putative transcription factor binding sites using the 
Transcription Factor Database (TRANSFAC) and Matlnspector
GENERATION OF PLASMID CONSTRUCTS
pGL3-Luciferase Reporter (Promega) and pSV-Galactosidase Control Vectors (Promega) 
provide a basis for die quantitative analysis of factors that potentially regulate mammalian 
gene expression. These factors may be cu-acting (promoters and enhancers) or trans-acting 
(various DNA-binding factors).
6pGL3-Basic Luciferase Reporter Vector: This vector lacks eukaryotic promoter and 
enhancer sequences. Expression of luciferase activity in cells transfected with this plasmid 
depends on the promoter activity of the insertion in certain cells. Without insertions, this 
vector serves as a control for the background activity.
pGL3-Control Luciferase Reporter Vector: This vector contains SV40 promoter and 
enhancer sequences, resulting in strong expression of luciferase gene in many types of 
mammalian cells. The control vector serves as positive control to monitoring transfection 
efficiency.
pSV-Galactosidase C Control Vector: This vector is co-transfected with the DNA of 
interest and acts as an internal control for transient expression assays.
Cloning: Various lengths of 5' upstream sequences were cloned into the promoter-less vector; 
pGL3-Basic itself and generated clones were tested for promoter activity. Constructs were 
generated by digesting the genomic clone, Bam5'C with BglWNcol, or KpnVSacl, or 
SmaVNcol. pGL3-Basic was digested and dephosphorylated followed by ligation with the 
digested genomic fragment using T4 DNA ligase. The clones were transformed into E. coli 
TOP 10 cells and plasmid DNA was isolated. Constructs were confirmed by dideoxy 
nucleotide sequencing.
The pGL3-luciferase expressing constructs made -3451 CART-LUC, spanning -3451 to +23, 
-641 CART-LUC, spanning -641 to +30, and -102 CART-LUC, spanning -102 to + 23 to +30 
where +1 is the predicted site of transcription initiation. Furthermore, mutated 641CART- 
LUC with abrogated CRE site and CREB dominant negative mutant, (pCMV500-A-CREB) in 
which basic residues within the bZIP domain have been mutated to acidic residues, referred to 
as A-CREB were generated.
TRANSFECTION
For each transfection, 2 |ig of one of the pGL3-luciferase expressing constructs, 2pg of pSV- 
p-Galactosidase Vector and 6 pi of FuGENE 6 Transfection Reagent (Roche) were mixed in 
the appropriate serum-free media and incubated at 25 °C for 45 minutes following the 
manufacturer’s instruction. 100 pi of the complexed DNA/FuGENE 6 mixture was added to 
each well and incubated for 18 hours at 37 °C under 5 % CO2. In some cases, 2 ml of 
supplemented media containing 20 pM forskolin was added and incubated for additional 
amounts of time. Cells were lysed and luciferase expression measured using the Luciferase 
Assay System (Promega).Luciferase activity was quantified using a luminometer. (3- 
Galactosidase activity was measured using the P-Galactosidase Enzyme assay system 
(Promega) and the absorbance read at 420 nm. Protein concentration was determined using 
the Bradford method (Bio-Rad Protein Assay). In all experiments, luciferase expression was 
normalized to P-Galactosidase activity using equal protein concentration. Statistical 
significance was determined using one-way ANOVA followed by a Tukey Test or a Student 
t-test (SigmaStat 2.O.).
RNase PROTECTION ASSAY
10 pg of RNA from AtT20, GH3 and PC 12 cells was dissolved in High-Speed Hybridization 
buffer (Ambion) and 32P-CART RNA antisense probe was added to each sample. After 20 
minutes hybridizing at 68 °C, the probe and RNA were digested with an RNase mixture at
737 °C for 30 minutes. After inactivation and precipitation of samples, the protected fragments 
were subjected to 8% denaturing polyacrylamide gel electrophoresis. Then, the gel was dried 
and exposed to X-ray film at minus 80 °C for 15 hours.
NORTHERN BLOT ASSAY
Total RNA was isolated from frozen rat cerebellum and hypothalamus or GH3 cells. Tissues 
(50-100 mg) were homogenized in 1 ml of Trizol Reagent (Life Tech.) using a power 
homogenizer. 107 GH3 cells were lysed in 1 ml of Trizol Reagent and RNA was isolated 
according to the manufacturer's recommendation. Total RNA was run in a 1.2 % 
formaldehyde agarose gel. RNA was transferred by capillary action in the presence of lOx 
SSC and fixed by UV cross-linking. Hybridization buffer was changed and 2x 106 cpm of a 
32P-labeled cocktail consisting of 2 or 3 distinct oligonucleotides was incubated at 50 °C for 
24 hours. Oligonucleotides were 5' end labeled by using y-32P-ATP (6000 Ci/mmol) and 
polynucleotide kinase (Stratagene). The CART cocktail consisted of three oligonucleotides 
with the following sequence: 5’TGAAAACAAGCACTTCAAGAGGAAAG3\
5 'TGCAACGCTTCGATCTGC AAC ATAG3 ’, 5’CTCATGCGCACTCTCTCCAGCG3\
Blots were stripped and re-probed with the GAPDH probe. CART mRNA levels were 
normalized to GAPDH mRNA.
WESTERN BLOT ASSAY
Total protein was extracted in 100 pi of lysis buffer containing the following protease and 
phosphatase inhibitors: 5 nM ocadaic acid, 200 pM sodium othovanadate, lx protease 
mixture (Maniatis) and 0.2 mM PMSF.Equal amounts of lx sample buffer were added to 
25pg of protein lysate. The gel was run at 120V for 2 hours and then electrically transferred 
overnight (50V at 4 °C) onto Immobilon -P membrane (Millipore) using a transfer buffer. The 
blot was incubated in PBS-T blocking buffe for 1 hour. After the initial blocking step, the blot 
was incubated in blocking buffer that contained anti-CREB antibody at a 1:500 dilution 
(Santa-Cruz) for 1 hour at room temperature. Then the blot was washed at room temperature 
and then incubated with a horseradish peroxidase (HRP)-conj ugated secondary antibody, anti­
rabbit IgG (Santa Cruz). CREB binding was detected using a chemiluminescent detection kit 
(ECL+Plus). The blot was washed with 0,2 M NaOH to remove previous protein complexes 
and re-incubated overnight at 4 °C with anti-phosphorylated - CREB antibody (P- CREB) 
(Cell Signaling).
ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA)
DNA-protein interactions were studied by EMSA. Nuclear protein extracts were prepared 
from forskolin-treated GH3 cells as described by Szeberényi et al. (1998). Total nuclear 
protein (15 pg ) was incubated with 2 ng of 32P-5'end-labeled oligonucleotide, containing the 
CART-CRE site (5’AGCATTGACGTCA3’) Total nuclear protein extract and labeled 
oligonucleotide were incubated for 10 minutes at room temperature. In some cases, a 20- or 
100-fold molar excess of a specific competitor (nonlabeled CART oligo), or 100-fold molar 
excess of a nonspecific competitor Oct 1 (5* TGTTGAGGGGACTTTCCCAGC 3') was added 
to the mixture, to assess the specificity of the DNA-protein binding complex before the 
addition of the labeled oligonucleotide. „Incubation with unlabeled oligonucleotide, the 32P- 
labeled CART oligonucleotide was added and incubation was continued for 20 minutes. For 
the supershift assay, 2 pg of CREB antibody (Santa Cruz) was incubated with the nuclear 
extract and the 32P-labeled CART oligonucleotide for 45 minutes. Supershift analysis was 
also done using 4 pg of P-CREB antibody (Santa Cruz). P-CREB antibody was incubated 
with the nuclear protein extract in binding buffer for 30 minutes at room temperature, 
followed by addition of the 32P-labeled CART oligonucleotide and incubated for another 45
8minutes. The DNA -protein complexes were separated by electrophoresis on a 6% non­
denaturing polyacrylamide gel. Gels were run (120 V) in the presence of 0.5x TBE buffer for 
1.5 hour at 4 °C. Dried gels were exposed for 24 hours and analyzed by using a 
Phospholmager.
EXPERIMENTAL RESULTS
Computer search for enhancer elements in the CART promoter region
To understand the molecular mechanism involved in the transcriptional regulation 
of CART gene expression, a mouse BAC genomic library was screened using rat CART 
cDNA probe. One hybridization clone was identified (Adams et al. 1999). A BamHl subclone, 
BAM5’C, containing the entire CART gene was generated. The CART 5’ flanking region in 
BAM5’C (BglU / SacI segment) was sequenced. The sequenced region was analyzed for 
putative transcription factor binding sites. This analysis revealed a region in the mouse CART 
gene 5’ upstream sequence containing a cluster of transcription factor binding sites, including 
a canonical cyclic AMP response element (CRE), two AP-1 sites, one SP1 and several AP2 
sites, along with a TATA-like sequence and an E-box .There is also a STAT-response 
element, TT(N)6AA, in an overlapping STAT/CRE/AP1 site. Further upstream, there is a 
putative binding site for the pituitary-specific transcription factor Pit-1, AWWWTATNCAT, 
where W is either an A or T. The CART gene upstream sequence was further analyzed using 
a neural network promoter predicting algorithm in order to predict transcription initiation sites 
for the mouse CART gene. The transcription initiation for the mouse CART gene was 
predicted at the A located 19 nucleotides upstream of the initiating AUG codon in agreement 
with the previously published rat and human 5' ends. The alignment of the mouse proximal 
promoter region with the corresponding human region (Accession Number NT019389) 
identified a 320 bp region immediately upstream from the CART coding sequence that shares 
83.4% nucleotide identity. The region contains the binding site for the clustered set of 
transcription factors, including the overlapping CRE/AP1/STAT site.
Assessing the transcription factor binding sites for promoter activity
To examine the regulation of CART gene promoter, GH3 mouse pituitary 
adenoma cell line served as an in vitro model. Furthermore, to compare the activities, predict 
tissue specificity, and determine the importance of certain CART promoter regions in the 
gene regulation, AtT20 and PC 12 cell lines were used as well as an in vitro model.
The activity of various 5’-proximal regions of the CART gene was tested for the ability to 
drive gene expression when cloned into pGL3-Basic vector upstream of the luciferase gene. 
Three luciferase expressing constructs were made and tested, -3451CART-LUC, -641CART- 
LUC, and -102CART-LUC that contain 3451, 641, and 102 bp mouse CART 5’ upstream 
sequence (+1 is the predicted site of transcription initiation), respectively. The -102CART- 
LUC construct contains the TATA-like box and an SP1 site. The -641CART-LUC construct 
contains the STAT/CRE/AP1 composite site and the -3451CART-LUC contains a putative 
Pit-1 binding site. Pit-1 is a transcription factor belonging to the POU domain proteins that is 
expressed exclusively in the central nervous system and in the pituitary.
Cells were transiently co-transfected with pSV-p-Galactosidase and one of the CART 
promoter containing constructs. Luciferase activity of each construct was compared to that 
produced by pGL3-BASIC, the parent vector that lacks a promoter for background activity.
9pGL3-C0NTR0L, which has SV40 promoter to drive luciferase expression, was used as a 
positive control. In GH3 cells, pGL3-CONTROL had a 6-fold increase in luciferase activity 
above pGL3-BASIC. This is similar to the 5.4-fold activation by -102CART-LUC, indicating 
that this segment of CART upstream sequence can function as a promoter and drive luciferase 
expression. Moreover, the -641CART-LUC construct containing a larger upstream segment of 
CART promoter produced much greater, 29-fold activity. A dramatic 59-fold increase in 
luciferase activity was observed after the -3451CART-LUC construct transfection, suggesting 
the importance of this region in mediating the promoter activity. Because the promoter 
analysis revealed a CRE element in the CART promoter, this element should respond to an 
elevated cAMP level in the cells.
Then, the endogenous CART gene was measured for responsiveness to forskolin 
treatment. GH3 cells were treated with 20 jiM forskolin for 0, 1, 3, 6, 12 and 24 hours and 40 
|ig total RNA was analyzed by Northern blot analysis. Forskolin treatment increased CART 
mRNA levels compared to 0 hour, control exposure. The involvement o f protein kinase A 
(PKA) was also tested. In the same experiment, some GH3 cells were treated with 30 pM 
H89, a selective inhibitor of PKA for 2 hours prior to and during forskolin treatment. The 
time course showed that the maximal increase in CART mRNA levels occurred after 6 hours 
of forskolin treatment. Treatment with H89 prior and during forskolin treatment reduced 
CART mRNA level up to 50%. This result confirms that cAMP is a second messenger for 
positive regulation of CART gene expression and PKA as protein kinase is also involved in 
the hypothetical transcription pathways of CART gene.
To determine which cis-elements present in the CART promoter were responsible 
for the responsiveness to cyclic AMP induction by forskolin, two luciferase expressing 
constructs were tested. The -641CART-LUC and -102CART-LUC constructs were 
transfected into GH3 cells and 18 hours after transfection media was changed and cells were 
treated with 2Q|iM forskolin for 7 hours. A 2-fold increase in luciferase activity after forskolin 
treatment was produced with -641CART-LUC, while no statistically significant increase in 
luciferase activity was observed with -102CART-LUC and pGL3-CONTROL. This suggests 
that the region between -102 and -641 containing overlapping STAT/CRE/AP1 transcription 
factor binding sites that are responsive to cyclic AMP.
A comparison of luciferase activity between -641CART-LUC and pGL3-CONTROL after 
forskolin treatment showed that -641CART-LUC exhibits a continuous increase in expression 
beginning at 1 hour and continuing through 48 hours. The promoter activity of -641C ART- 
LUC was examined in AtT20 and PC12 cells as well. -641CART-LUC showed higher 
activity in PC 12 cells than in AtT20 cells. However, promoter activity was the highest in GH3 
cell (29-fold above background). Forskolin treatment did not have any significant effect on 
luciferase expression of -641CART-LUC construct in PC12 and AtT20 cells. The high 
activity of -641C ART-LUC in GH3 cells, and the lower activity in PC12 and AtT20 cells 
suggest that the STAT/CRE/AP1 overlapping transcription binding sites enhance expression 
in a cell type specific manner.
Additionally, a mutation that abrogated the CRE site in -641CART-LUC 
construct resulted in a 4.7-fold drop of luciferase expression in GH3 cells after forskolin 
treatment. All these results together delineate the relevance of the CRE transcription binding 
site on the CART promoter in GH3 cells. Also, these findings propose that this overlapping 
STAT/CRE/AP1 site plays an important role in the determination of tissue specificity of 
CART gene expression.
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Characterizing the putative transcription factors and their involvement in the regulation 
of the CART gene
Subsequently, electromobility shift assays were carried out to identify in 
particular the transcription binding sites that are responsive to elevated cAMP level and 
responsible for the promoter activity in transfected GH3 cells and the induced endogenous 
CART mRNA expression after forskolin treatment. A 27-bp double-stranded oligonucleotide 
containing the CRE site, corresponding to nucleotides -153 to -127 of the CART promoter, 
was synthesized and 5’ end labeled with 32P, referred to as CART oligo.
In order to test if this CRE site binds protein factors from GH3 cells, nuclear 
extracts from cells treated with 20 pM forskolin for varying periods of time (0.5, 1 and 3 
hours) were incubated with 32P-labeled CART oligo. Treatment with forskolin under the same 
conditions has been shown to enhance endogenous CART gene expression in GH3 cells.The 
32P-labeled CART promoter oligonucleotide clearly binds to nuclear factors in gels and results 
in the detection of a shifted DNA/protein complex. The binding increased with forskolin 
treatment time, and addition of 20x excess unlabeted CART oligo served to assess the 
specificity of the DNA-protein binding complex. This experiment indicates that the GH3 
cells, in response to forskolin treatment, produced increased binding to the CART promoter 
oligonucleotide.
Western blotting study was conducted to examine whether the treatment with 
forskolin under the same conditions produced changes in CRE binding protein (CREB) and/or 
phosphorlylated-CREB (P-CREB) levels. CREB is a well-characterized transcription factor 
known to be activated by cAMP and binds to the CRE site o f promoters. Consequently, 
CREB became the first candidate for the transcription factor that can bind to the CRE site of 
CART proximal promoter and be accountable for the increased CART mRNA expression. It 
revealed an increased P-CREB level with duration of treatment with forskolin, while CREB 
levels remained unchanged. These results suggested that the nuclear protein binding to the 
CART promoter oligonucleotide could be P-CREB. Accordingly, mobility supershift assay, 
was used to detect if the protein binding to the CART promoter site would interact with 
CREB and P-CREB antibodies since an increase of P-CREB was observed by Western blot. It 
was found that CREB and P-CREB antibodies supershifted the CART oligo/protein complex. 
In addition, molar excess of unlabeled cold CART oligo competed with radiolabeled CART 
oligo, whereas an unrelated oligo (Octl) did not, indicating specificity in the CART 
oligo/protein complex. The CART oligo/protein/CREB antibody complex was found in both 
untreated and treated cells as expected. Similar data were found after 0.5, 1 and 6 hours of 
forskolin treatment as well.
To confirm the role of CREB transcription factor in CART gene regulation, a 
CREB dominant negative mutant, A-CREB was co-transfected with the -641CART-LUC 
construct into GH3 cells treated with forskolin. A-CREB functions by heterodimerizing with 
endogenous CREB transcription factor and preventing its interaction with the CRE element. 
GH3 cells, co-transfected with the A-CREB mutant had a 3.4-fold reduction in luciferase 
expression as compared to cells co-transfected with the empty vector.
As a result of the experiments, in GH3 cells, the transcriptional regulation of the CART gene 
after activation of the cAMP pathway is likely to be mediated by the CREB transcription 
factor.
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Investigating the importance of different signal transduction pathways in the regulation 
of CART gene
lonomycin, an antibiotic has been reported to trigger the release of Ca2+ ions from 
the intracellular storage resulting in an increase of P-CREB. GH3 cells were treated with 10 
. |iM ionomycin under the same condition as forskolin treatment. Northern blot analysis 
demonstrated a significantly changed expression pattern after 1 hour ionomycin treatment. It 
seems that Ca2+ ions are stronger activators for the CART gene than AC activation.
In order to test if the CRB site binds protein factors from ionomycin-treated 
extracts, GH3 cells were treated with 10 pM ionomycin for 0, 0.5,1 and 3 hours and were 
incubated with 32P-labeled CART oligo. Nuclear proteins bound to 32P-labeled CART oligo 
and these DNA/protein complexes were supershifted with CREB and P-CREB antibody. In 
the same gel, the lOOx excess of unlabeled API oligo (Promega) competed for the labeled 
CART oligo indicating that the same nuclear factor or factors have binding affinity to the 
CART and AP-1 oligo. The binding activity of 32P-CART after 1 h ionomycin treatment 
demonstrated increased binding to the probes, respectively.
CONCLUSIONS
CART mRNA expression has been reported to be altered in response to various 
stimuli including fasting, leptin, and psychostimulant drugs but the signal transduction 
pathways involved in the CART mRNA regulation have not been studied yet.
The aim of this work was to characterize the CART promoter regulation by 
identifying putative transcription factor binding sites in order to describe signal transduction 
pathways involved in the regulation of CART gene expression. Sequence analysis o f a 3.4 kb 
mouse genomic DNA fragment revealed a 320 bp region located upstream from the 
transcription start site, which is highly conserved between human and mouse CART gene. 
This region contains several transcription factor binding sites including an overlapping 
STAT/CRE/AP1 site located 148 nucleotides upstream from the predicted transcriptional 
initiation site. This binding may play an important role in the regulation of the CART gene.
The transient transfection system is the primary tool for identifying and 
characterizing the interaction of cis-acting elements with their corresponding fra/u-acting 
factors and associated cofactors in mammalian cells. In order to test the presumed promoter 
activity of the individual DNA fragment, different lengths o f the mouse CART promoter were 
transfected for transcriptional activity into the GH3 rat adenoma line. This comparative 
transfection analysis revealed diverse transcriptional expression patterns after forskolin 
treatment in accordance with the different lengths of the CART promoter. These studies 
indicate that this individual DNA fragment displays significant promoter activity, moreover a 
major role for the overlapping STAT/CRE/AP1 transcription binding site in the regulation of 
the CART gene. This suggestion is supported by the mutation of the CRE site in the - 
641CART-LUC construct that showed significant decrease in the promoter activity. In 
addition, -3451 CART-LUC displayed the highest promoter activity suggesting the 
importance of other transcription factor binding sites in CART gene expression. Additionally, 
the transfection studies on AtT20 and PC12 cells showed promoter activity considerably 
reduced indicating a highly tissue -  specific regulation of this promoter. Likewise, the Pit-1 
binding site at position -818 on the mouse CART promoter suggest the Pit-1 transcription 
factor involvement in a cell-type specific transcriptional activation of the CART gene. Pit-1 is
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a POU-homeobox transcription factor that is responsible for either the commitment or 
maintenance of somatotrop, lactotrop, and thyreotrop cell lineages in the pituitary.
To identify the possible regulation pathway/pathways, endogenous CART gene 
responsiveness to forskolin treatment was tested. Transcription activation of endogenous 
CART gene ín GH3 cells showed a continuous increase after cyclic AMP activation. In 
accordance with the recent scientific viewpoint this elevation was probably due to PKA 
activation since forskolin turns on the cAMP-PKA pathway. PKA stimulates different 
transcriptions factors including CREB. CREB is known to bind to CRE elements in the 
promoter of number of genes (e.g. somatostatin and tyrosine aminotransferas). Consequently, 
treatment with H89, an inhibitor of PKA, with simultaneous forskolin treatment, reduced the 
increase in the expression of endogenous CART mRNA. In summary, these studies together 
suggest that the CRE site in the CART proximal promoter could mediate the increased 
expression in CART mRNA levels in response to forskolin treatment via the PKA pathway.
Following this train of thoughts, it has been well described that the binding of 
cAMP to two PKA regulatory subunits, releases the catalytic subunits and enables them to 
phosphorylate target proteins. ATF/CREB family is one of the target proteins including 
several members, of which the CREB, CREM and ATF1 gene products are directly 
phosphorylated by the cAMP-dependent PKA. ATF/CREB family belongs to a larger leucine 
zipper family. This domain allows CREB, ATF1 and CREM to be able to bind to CRE sites 
as a dimer. The presence of highly conserved and related dimerization domains suggests that 
the different members of the CREB/ATF family might be able to form heterodimers and 
homodimers as well. Furthermore, composite CRE/API sites have been found in a number of 
genes in playing very important roles in neurotransmitter synthesis, including dopamine 
hydroxylase, prodynorphin, proenkephalin, and cholecystokinin.
CREB is one of the main transcription factors involved in many genes’ regulation 
in the brain; therefore, CREB became the first candidate, which may moderate the expression 
of CART gene via the PKA pathway by binding to the CRE site on the CART promoter. The, 
results of mobility shift assays pointed out that treatment of GH3 cells with forskolin 
produced an increased level of P-CREB via the PKA pathway that binds to the CART 
promoter oligonucleotide containing CRE/AP1 site. These findings are very important 
because phosphorylation of CREB affects the ability of dimerization with different bZIP 
partners or the phosphorylation at Ser 133 might trigger CREB binding to CRE. Transfection 
experiments with the dominant negative mutant CREB-A also supported a crucial role for 
CREB in the regulation of CART gene expression. On the other hand, it is a well-known fact, 
that increase in the intracellular Ca2 * level causes an elevation of P-CREB. Many kinases, 
some of whose activities are enhanced by Ca2 are capable of phosphorylating CREB in vitro, 
including Ca2+/calmodulin-dependent kinases I, II, and IV (CaMKI,II, and IV) and PKC. In 
this study, it was also demonstrated that the increase of intracellular Ca2+ level by ionomycin 
treatment induced the gene expression of CART through CREB recruitment to die CRE site 
of the promoter in GH3 cells. These observations indicate that the CART gene may be 
regulated by other signal transduction pathways activating CREB, not exclusively by cAMP- 
PKA. Additional studies are required to determine the precise role of intracellular Ca2* in the 
regulation of the CART gene. Moreover, the mobility shift assay of ionomycin-treated cells 
showed a competition between labeled CART probe and unlabeled AP-1 oligonucleotide 
indicating the possible role of other transcription factors (e.g. AP-1) in the regulation of 
CART gene expression.
The fact that other transcription factors can form complex with CRE can explain 
this phenomenon. After cAMP and Ca2+ stimuli, CREB makes different complexes involving
13
several transcription factors. The molecular mechanism that accounts for the 
CRE/AP1 specificities of bZIP proteins has been a focus of research since this DNA 
recognition motif was first identified in 1987. The CRE (TGACGTCA) and API 
(TGACTCA) target sites share the same consensus half-site and differ by only a single, 
central G-C base pair. It has been reported that the CRE/AP1 specificity of CREB is 
controlled by charged residues has interesting implications about how transcription factors 
seek and selectively bind to precise sequences within genomic DNA (Montclare et al. 2001) 
emphasizing the ease with which specificity can be altered through the formation of different 
heterodimers or through combinational interactions with cellular factor.
Recently, in vitro binding studies have indicated that phosphorylation of CREB on 
Ser 133 does not alter the affinity of CREB or a palindromic CRJB site (TGACGTCA; CART 
promoter has the same palindromic sequence), but it can be crucial at different levels of the 
transcription activation pathway for promoting target gene activation through recruitment of 
the 265-kDa, 2442 amino acid co-activator protein, CREB binding protein (CBP). CBP co­
activator is a member of acetyltransferase family (AT) including p300/CBP-associated factor 
(P/CAF), TAFu 250, steroid receptor coactivator-1 (NCo-l/SRC-1), p300/CBP-interacting 
protein (P/CIF), and pl60. These proteins are able to acetylate transcription factors (e.g. p53), 
histone proteins and other nuclear proteins.
Based on studies, in accordance with our results, the Ser-133 phosphorylation of 
CREB is both necessary and sufficient for complex formation promoting die interaction 
between KIX domains. This interaction domain of CBP is required for binding to the P- 
CREB. CBP can serve as a molecular bridge that allows CREB to recruit and stabilize the 
RNA polymerase II (Pol II) transcription complex at the TATA box. Some studies have 
shown that the AT containing domain of CBP can only stimulate transcription from certain 
promoters and that the PKA activation of CREB required CBP, P/CAF and P/CIF. The 
diversity amongst the AT domains in different co-activators may account for their observed 
promoter selectivity.
As mentioned above, CREB forms heterodimers with its family members (ATF1, 
CREM, ICER) and seems to make complexes with other factors binding to the CRE site, for 
example c- Jun and NF-kB through CBP. In this regard, our findings postulate a hypothesis in 
which the direct and indirect interaction of different transcription factors, co-activators with 
CREB involving the alternation of AT activity are also involved in the CART promoter 
regulation. Additional mutational analysis and mobility shift assay of the STAT/CRE/AP1 
composite site with different transcription factors including CBP will be important in 
identifying which transcriptional binding sites and factors beside CREB are involved in the 
Ca2+/cAMP responsiveness of CART promoter.
The present results may be of physiological significance since cocaine 
administration increases P-CREB levels in the brain and increases CART mRNA levels in the 
striatum as well. Since the CART peptide appears to play a role in the action of diverse 
neurotransmitters and has itself multiple functions in the central and peripheral nervous 
system (Table 1), the further investigation of the regulation of the CART gene can elucidate 
the background of its multiple functions. On the other hand, using CART gene promoter 
studies as a model for investigating gene regulation, can provide a new approach helping to 
understand the complex regulation of genes and their expression in central nervous system.
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